+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Emergent BioSolutions Inc (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, travel health, emerging health crises, nuclear and explosives (CBRNE), emerging infectious diseases and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent's pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.

Emergent BioSolutions Inc Key Recent Developments

  • Apr 19, 2023: Emergent BioSolutions to release first quarter 2023 financial results and conduct conference call on May 9, 2023
  • Feb 27, 2023: Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
  • Feb 06, 2023: Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
  • Nov 08, 2022: Emergent BioSolutions Reports Financial Results For Third Quarter 2022

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Emergent BioSolutions Inc - Key Facts
  • Emergent BioSolutions Inc - Key Employees
  • Emergent BioSolutions Inc - Key Employee Biographies
  • Emergent BioSolutions Inc - Major Products and Services
  • Emergent BioSolutions Inc - History
  • Emergent BioSolutions Inc - Company Statement
  • Emergent BioSolutions Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Emergent BioSolutions Inc - Business Description
  • Business Segment: Contract Development and Manufacturing Services
  • Performance
  • Business Segment: Contracts and Grants
  • Performance
  • Business Segment: Product Sales
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Emergent BioSolutions Inc - Corporate Strategy
  • Emergent BioSolutions Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Emergent BioSolutions Inc - Strengths
  • Emergent BioSolutions Inc - Weaknesses
  • Emergent BioSolutions Inc - Opportunities
  • Emergent BioSolutions Inc - Threats
  • Emergent BioSolutions Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Emergent BioSolutions Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 19, 2023: Emergent BioSolutions to release first quarter 2023 financial results and conduct conference call on May 9, 2023
  • Feb 27, 2023: Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
  • Feb 06, 2023: Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
  • Nov 08, 2022: Emergent BioSolutions Reports Financial Results For Third Quarter 2022
  • Oct 27, 2022: SAB Biotherapeutics announces exclusive manufacturing partnership with Emergent BioSolutions
  • Oct 18, 2022: Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
  • Sep 27, 2022: Emergent acquires global rights for oral smallpox antiviral from Chimerix
  • Aug 10, 2022: Emergent BioSolutions to Participate in Investor Conferences
  • Aug 01, 2022: Emergent BioSolutions Reports Financial Results for Second Quarter 2022
  • Jul 18, 2022: Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Emergent BioSolutions Inc, Key Facts
  • Emergent BioSolutions Inc, Key Employees
  • Emergent BioSolutions Inc, Key Employee Biographies
  • Emergent BioSolutions Inc, Major Products and Services
  • Emergent BioSolutions Inc, History
  • Emergent BioSolutions Inc, Other Locations
  • Emergent BioSolutions Inc, Subsidiaries
  • Emergent BioSolutions Inc, Joint Venture
  • Emergent BioSolutions Inc, Key Competitors
  • Emergent BioSolutions Inc, Ratios based on current share price
  • Emergent BioSolutions Inc, Annual Ratios
  • Emergent BioSolutions Inc, Interim Ratios
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Emergent BioSolutions Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Emergent BioSolutions Inc, Performance Chart (2018 - 2022)
  • Emergent BioSolutions Inc, Ratio Charts
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Elusys Therapeutics Inc
  • Merck & Co Inc
  • Genentech USA Inc
  • Intralytix Inc
  • Soligenix Inc
  • GC Biopharma Corp
  • GSK plc
  • Novartis AG
  • Greffex Inc
  • Hikma Pharmaceuticals USA Inc
  • Amgen Inc
  • Altimmune Inc
  • Altimmune Inc
  • Amgen Inc
  • Amphastar Pharmaceuticals Inc
  • Elusys Therapeutics Inc
  • GC Biopharma Corp
  • Genentech USA Inc
  • Greffex Inc
  • GSK plc
  • Hikma Pharmaceuticals USA Inc
  • Intralytix Inc
  • Merck & Co Inc
  • Mitsubishi Tanabe Pharma Corp
  • Teva Pharmaceutical Industries Ltd
  • Soligenix Inc
  • SIGA Technologies Inc
  • Novartis AG
  • SIGA Technologies Inc
  • Mitsubishi Tanabe Pharma Corp
  • Teva Pharmaceutical Industries Ltd
  • Amphastar Pharmaceuticals Inc